本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
--At the dosage of 800 mg ASC10, twice daily (BID), the exposure of the active drug, ASC10-A, is comparable to that of monupiravir's --ASC10 at 800 mg, BID is safe and well tolerated --Dosage of 800 mg ASC10, BID was selected for Phase IIa clinical trial for respiratory syncytial virus (RSV) infection in the U.S. and Phase III clinical trial for SARS-CoV-2 infection in China HANGZHOU and SHAOXING, China, Feb. 21, 2023 /PRNewswire/ -- AscletisPharma Inc. (HKEX: 1672, "Ascletis") today presented positive data from Phase I clinical trial of ASC10, a broad-spectrum antiviral double prodrug, at Conference on Retroviruses and Opportunistic Infections (CROI) 2023 in Seattle, the U.S. ASC10 is an oral double prodrug. After oral administration, both ASC10 and single prodrug molnupiravir are rapidly and completely converted in vivo into the same active drug ASC10-A, also known as β-D-N4-hydroxycytidine (NHC) or EIDD-1931. Preclinical studies show that ASC10-A has broad-spectrum antiviral activities including potent activities against both SARS-CoV-2 viruses, monkeypox and respiratory syncytial virus (RSV). Results from the Phase I clinical trial showed at the dosage of 800 mg ASC10, twice daily (BID), the exposure of the active drug, ASC10-A, is comparable to that of monupiravir's. ASC10 was safe and well tolerated, and the increase in plasma exposure of ASC10-A was dose-proportional across the range of doses tested (50 mg to 800 mg) with no accumulation and minimal food effect. Dosage of 800 mg ASC10, twice daily was selected for Phase IIa clinical trial for RSV infection in the U.S. and Phase III clinical trial for SARS-CoV-2 infection in China. Ascletis has been granted the patent of ASC10 and its derivatives, and their uses to treat multiple virus infections including SARS-CoV-2, monkeypox virus and RSV from the United States Patent and Trademark Office (USPTO). Ascletis is the first Chinese biotech company which has been granted a patent by the USPTO for its in-house developed oral viral polymerase inhibitor and its derivatives. About CROI The Conference on Retroviruses and Opportunistic Infections (CROI) was established in 1993 to facilitate academic exchange in the epidemiology and biology of human retroviruses and associated diseases. CROI features the best and most consequential original research in human immunodeficiency virus (HIV), hepatitis viruses, SARS-CoV-2, monkeypox virus, and other viral infections and their related conditions. The CROI 2023 will be held in Seattle, Washington, the U.S. from February 19 to 22, 2023. About Ascletis Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange (1672.HK), covering the entire value chain from discovery and development to manufacturing and commercialization. Led by a management team with deep expertise and a proven track record, Ascletis focuses on three therapeutic areas with unmet medical needs from a global perspective: viral diseases, non-alcoholic steatohepatitis (NASH) and oncology. Through excellent execution, Ascletis rapidly advances its drug pipeline with an aim of leading in global competition. To date, Ascletis has three marketed products, i.e. ritonavir tablets, GANOVO® and ASCLEVIR®, and 23 drug candidates in its R&D pipeline. The most advanced drug candidates include ASC22 (HBV functional cure), ASC10 and ASC11(oral small molecules for COVID-19 treatment), ASC40 (recurrent glioblastoma), ASC42 (PBC, primary biliary cholangitis), and ASC40 (acne). For more information, please visit www.ascletis.com.
YOKOHAMA, Japan, Feb. 21, 2023 /PRNewswire/ -- On January 25, 2023, a foreign national was arrested on suspicion of illegally importing livestock products into Japan using international mail. Experience the full interactive Multichannel News Release here: https://www.multivu.com/players/English/9141051-animal-quarantine-service-vietnamese/ Quarantine detector dogs identify meat, fruits, and other items at the international post office. The person arrested on this occasion is suspected of attempting to bring livestock products such as meat products, which are prohibited from being imported into Japan, together with other foodstuffs including items of confectionery from overseas using international mail on multiple occasions. In order to prevent the invasion of livestock infectious diseases, it is prohibited by law in Japan to bring meat such as pork and chicken and meat products such as sausages and ham from many countries and regions including Asia, regardless of the quantity or mode of transportation. When livestock products are brought into Japan illegally, there is a possibility of a maximum of 3 years imprisonment or a fine of up to 3 million yen (up to 50 million yen for businesses). With an increasing outbreak of African Swine Fever, a highly lethal disease characterized by hemorrhagic lesions throughout the body, in Asian countries, the Animal Quarantine Service in Japan (AQS) has been strengthening the inspection of international mail and hand luggage arriving from overseas by, for example, increasing the number of animal and plant quarantine detector dogs. According to preliminary figures announced in 2022, 54,429 cases (35,729kg) of illegal livestock products imported as the personal effects (hand luggage) of travelers and 52,944 cases (85,683kg) of illegal livestock products imported as international mail were discovered. The amount of meat products discovered in international mail has risen to a daily average of over 234 kgs. When traveling to Japan from overseas or sending international mail to Japan, it is necessary to make sure that you do not bring or send any livestock products prohibited from being brought into Japan. Japan Animal Quarantine Service http://www.maff.go.jp/aqs/english/product/import.html Contact:Animal Quarantine Service, Planning and Coordination DivisionEmail: aqs.yokkikaku@maff.go.jphttps://www.maff.go.jp/aqs/languages/info.html Quarantine detector dogs are also on duty at airports. Meat products that the arrestee tried to bring in by international mail. Even meat products sold in stores are prohibited from being brought into Japan. It is forbidden to bring any meat products into Japan, including those that have been made into meat floss or snacks.
SINGAPORE, Feb. 21, 2023 /PRNewswire/ -- Singapore-based molecular diagnostics lab group iGene Laboratory announces the launch of FetalExome test service. FetalExome test is a whole exome sequencing (WES) test available for women with potentially complicated pregnancies. The test examines and analyses the gene regions that code for proteins, known as the exome, which plays a critical role as these proteins form the building blocks of cells and allows specialists to diagnose fetal abnormalities and reveal the causes of fetal complications. FetalExome is ordered when prenatal ultrasound imaging detects structural anomalies that is suggestive of genetic causes. Fetal structural anomalies are common and affect about 2-4% of pregnancies. The American College of Medical Genetics and Genomics (ACMG) recommends the use of WES when a diagnosis cannot be obtained using routine prenatal methods in a fetus with one or more significant anomalies.1 FetalExome is offered as a trio analysis where sequencing is performed on both parents and the fetus for timely clinical management and decision-making.2 Chief Executive of iGene Laboratory, Kane Black remarked, "As arguably the fetal-maternal health pioneer in South East Asia, we are proud to launch another test to support mother's to be and their babies". Mr. Black further commented "with thousands of genes analysed at the same time, rather than one or a few genes at a time, FetalExome will allow doctors to potentially identify and/or administer the best specific treatments efficiently". 1. Monaghan KG, Leach NT, Pekarek D, Prasad P, Rose NC; ACMG Professional Practice and Guidelines Committee. The use of fetal exome sequencing in prenatal diagnosis: a points to consider document of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2020;22(4):675-680. doi:10.1038/s41436-019-0731-7 2. Chau MHK, Choy KW. The role of chromosomal microarray and exome sequencing in prenatal diagnosis. Curr Opin Obstet Gynecol. 2021;33(2):148-155. doi:10.1097/GCO.0000000000000692 About iGene Laboratory: iGene Laboratory Pte. Ltd is a College of American Pathologists (CAP) Accredited Next Generation Sequencing Laboratory that provides diagnostic testing, with a focus on women's and fetal Health, clinical research (CRO) and COVID-19 testing services. The company was the first to launch Non Invasive Prenatal Testing (NIPT) in Singapore and continues today on this foundation of pioneering diagnostics. iGene Laboratory is a subsidiary of INEX Innovate Pte Ltd, one of Asia's fastest growing molecular diagnostics developers. Founded by veteran maternal fetal medicine specialists, INEX is uniquely positioned to identify and address clinically unmet needs within the fetal health and women's oncology landscape, with a broad commercial portfolio of validated tests and 48 key patents. For more information please visit: www.igenelab.com or www.inex.sg
BBT-401 meets safety endpoints achieved in previous clinical studies The drug candidate did not achieve an improved clinical response compared to the placebo study group 54.5% of the treatment cohort exhibited a valid treatment response to orally administered BBT-401 SEONGNAM, South Korea, Feb. 21, 2023 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company focused on developing novel drugs for inflammation, fibrosis and oncology, announced the results of its multinational Phase 2a clinical study (NCT 04596293) to evaluate the safety and efficacy of orally administered BBT-401 in subjects with active ulcerative colitis (UC). The Phase 2a mid-to-high dose cohort study included 38 patients enrolled at 37 clinical sites located in the U.S., New Zealand, the Republic of Korea, Poland, and Ukraine. During the induction and extension phases of the study, both groups treated with BBT-401 (800mg) once daily and twice daily failed to meet the primary efficacy endpoint of the clinical response rate at Day 57, as measured by reduction of ≥3 points and a ≥30% improvement from the baseline of total Mayo score. Clinical response rates (95% CI) on Day 57, based on centrally read Mayo endoscopic subscores, were 63.6% (30.8%, 89.1%) for the placebo twice daily treatment group; 54.5% (23.4%, 83.3%) for placebo once and BBT-401 once daily treatment group; and 54.5% (23.4%, 83.3%) for the BBT-401 twice daily treatment group. The study met the primary safety endpoint. The primary safety endpoints were adverse events (AEs) and serious adverse events (SAEs). The safety and tolerability profile observed in the Phase 2a study was consistent with the safety profile of BBT-401 demonstrated in previous studies. James Lee, founder and CEO of Bridge Biotherapeutics, said the company is fully committed to continued development of BBT-401. "We are grateful to the patients, investigators and medical professionals who participated in this clinical study," said Lee. "Although we did not achieve the primary efficacy endpoint in the treatment groups with BBT-401, we remain committed to the development of BBT-401. We believe this first-in-class Pellino-1 inhibitor remains an important candidate to address unmet medical needs in the treatment of ulcerative colitis. We are also encouraged by the safety and tolerability results of the study. Bridge Biotherapeutics will continue to advance development of BBT-401 to further improve the delivery of the drug and the treatment efficacy." Prior to the Phase 2a study, the company first explored drug efficacy and safety in patients with ulcerative colitis through a BBT-401 low-dose cohort study, conducted in the United States from April 2019 to July 2020. After the low-dose cohorts, the company developed a new formulation of BBT-401 that improved drug delivery to the colon and ileum. The Phase 2a, mid-to-high dose study confirmed that drug delivery distribution profiles were improved. Based on the drug delivery result, the company will continue to seek opportunities for enhancing the drug delivery to the intestine with further formulation improvements to BBT-401. About BBT-401 BBT-401, an investigational drug with the potential to exhibit treatment efficacy in inflammatory diseases such as ulcerative colitis, is a GI-tract restricted small molecule Pellino-1 inhibitor. Pellino serve as scaffold that bind to proteins in inflammatory signaling pathways, including IRAK4, MyD88 and to RIPK1, in various physio-pathological conditions. About Bridge Biotherapeutics, Inc. Bridge Biotherapeutics Inc., based in the Republic of Korea and the U.S. is a publicly-traded, clinical-stage biotech company founded in 2015. Bridge Biotherapeutics is engaged in the discovery and development of novel therapeutics, focusing on therapeutic areas with high unmet needs including ulcerative colitis, fibrotic diseases, and cancers. The company is developing BBT-401, a first-in-class Pellino-1 inhibitor for the treatment of ulcerative colitis, BBT-877, a novel autotaxin inhibitor for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF), and BBT-176, a potent targeted cancer therapy for non-small cell lung cancer (NSCLC) with C797S triple EGFR mutations. Learn more at https://www.bridgebiorx.com/en.
With More Than 20 Years of Experience, Rabeau to Lead Company's Expansion Down Under MELBOURNE, Australia, Feb. 21, 2023 /PRNewswire/ -- Infleqtion, the global quantum leader, today announced the addition of Jim Rabeau as incoming President, Infleqtion Australia. Jim most recently served as Director of Quantum Technologies at Australia's national science agency, CSIRO. As President, Jim will be responsible for Infleqtion's expansion into Australia and establishing the Asia-Pacific quantum computing and technology facility at Swinburne University of Technology. Jim Rabeau "Jim brings a unique background to Infleqtion, understanding quantum both from the academic and commercial perspectives," said Scott Faris, CEO, Infleqtion. "Jim has a proven track record working at the cutting edge of quantum technology and will serve as a visionary leader in Australia as we work to expand our global footprint." At CSIRO, Jim led the national Quantum Technology Future Sciences Platform to build a cross-disciplinary program of research and development in quantum technology. Prior, Jim served as a Professor of Physics and Deputy Director at the Sydney Nano Institute at the University of Sydney. He also worked as a Principal Program Manager of Quantum Computing at Microsoft. "Infleqtion is at the forefront of quantum innovation, leveraging its technology to develop commercial products beyond computing," said Jim Rabeau, incoming President, Infleqtion Australia. "I'm energized by the work this talented team has already accomplished, and look forward to continuing this growth trajectory here at home." Rabeau's appointment comes on the heels of a momentous year for Infleqtion in Australia. Most recently, the company announced an A$29 million investment from Breakthrough Victoria to create the Infleqtion-Swinburne Quantum Technology Centre, supporting quantum breakthroughs with commercial potential and expanding the state's quantum capabilities. About InfleqtionInfleqtion is building an ecosystem of quantum technologies and commercial products for today, that will drive the company and the entire industry toward tomorrow. The company believes in taking quantum to its limit and leading from the edge. Infleqtion is built on 16 years of pioneering quantum research from ColdQuanta. Its scalable and versatile quantum technology is used by organizations around the globe and deployed by NASA on the International Space Station. Infleqtion is based in Boulder, CO, with offices in Chicago, IL; Madison, WI; Melbourne, AU and Oxford, UK. Find out how Infleqtion is building the future at www.Infleqtion.com. Photo - https://mma.prnasia.com/media2/2005197/Jim_Release_Photo.jpg?p=medium600 Logo - https://mma.prnasia.com/media2/1961782/INFLEQTION_LOGO_LANDSCAPE_GRAD_RGB_Logo.jpg?p=medium600
Retold Recycling receives Mark Cuban's seal of approval on their #NoLandfill mission SAN FRANCISCO, Feb. 21, 2023 /PRNewswire/ -- Retold Recycling - a convenient and sustainable textile recycling start-up founded by two Aussies - received a $300,000 deal in exchange for a 25% stake in their company from famed Shark, Mark Cuban. California-based Retold Recycling empowers consumers by making it convenient to responsibly dispose of clothing and other fabrics, diverting that waste from landfill. Customers can purchase ready-to-ship Retold bags to fill with any unwanted household textiles, eliminating the burden of determining the best recycling solution for each submission. Items are sorted and given a second life - clearing to thrift stores, rag companies, downcyclers, and soon, circular fiber producers. Since its 2020 launch, Retold Recycling has diverted over 100,000 pounds (50 tons) of fabric waste from landfill. The two Australians, Amelia Trumble and Alan Yeoh - who met in NYC as executives at MAC Cosmetics - stood before the Sharks during Friday night's episode of the American TV show to deliver their pitch, explaining their '#NoLandfill' vision and how the brand is tackling the major issue of textile waste with this first and only solution of its kind in the USA. Cuban saw the opportunity for the business to scale into retail and to truly own the category that Retold has innovated. Amelia Trumble, CEO of Retold Recycling shares: "Despite playful banter about our accents and plenty of drama in the Tank, Mark was able to cut through the noise and immediately understood our vision and how we could scale. His past history of betting on solutions that help society at large meant that we knew he was the perfect Shark for us!" Retold is planning to develop new recycling solutions, expand into retail partners, continue to upgrade its technology, and add to its growing list of brand partners which have included Jenni Kayne, Verizon, Boody, and Vitamin A Swim. About Retold Recycling Retold Recycling is a convenient service for recycling household textiles, sustainably diverting them from landfills. Items sent in each yellow Retold bag are sorted before going to thrift stores, reuse partners, and upcyclers. With a passion for eradicating landfill at its core, Retold Recycling aims to build a community of subscribers "woke" to the tons of textiles thrown away daily, via its mantra and vision: #nolandfill.
A12 藝術空間
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
